Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search criteria or primary empirical trial data
PubMed 34621137 · doi:10.1177/11795514211006071
What was done
The authors conducted a narrative review summarizing the therapeutic potential of animal venom-derived peptides for diabetes and related metabolic disorders, examining established agents such as exendin-4 and candidate molecules from bees, cone snails, sea anemones, scorpions, snakes, and spiders.
What was found
The abstract contains no numerical findings, sample sizes, or effect estimates. It reports qualitatively that venom-derived peptides offer bioactivity, specificity, and stability relative to synthetic compounds, and that molecules from various venomous taxa show potential for glycemic control and modulating insulin secretion pathways.
Why it matters
Venom-derived compounds provide validated structural templates for antidiabetic drug discovery and functional tools for investigating cell signaling in metabolism.
Limits
The publication is a narrative review with no systematic search methodology, risk-of-bias assessment, or pooled analysis. Beyond established agents like exendin-4, the therapeutic applications for emerging venom peptides remain in early drug discovery stages without reported human efficacy or safety data in the abstract.
Cited by
- supports Natural GLP-1-like compound exendin-4 was discovered in the saliva of the Gila monster.